{"id":"W4283695118","doi":"10.1136/annrheumdis-2022-eular.1862","title":"POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"Medac; Celgene; Biogen; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Placebo; Internal medicine; Apremilast; Adverse effect; Clinical trial; Pharmacology; Gastroenterology; Arthritis; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008102857,0.0006956079,0.001519584,0.0002695809,0.0002415739,0.0008713632,0.0003970604,0.001192896,0.003957734],"category_scores_gemma":[0.000698072,0.0002824016,0.000999275,0.0002801354,0.000494468,0.0007817824,0.0001559922,0.002406002,0.001437202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005685412,"about_ca_system_score_gemma":0.0005299766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003657964,"about_ca_topic_score_gemma":0.000907819,"domain_scores_codex":[0.9995934,0.0001716657,0.00002945611,0.00007450468,0.0000599719,0.00007101839],"domain_scores_gemma":[0.999613,0.0001000057,0.00008687279,0.0000305748,0.00003604751,0.0001334799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4357279,0.008116284,0.009787166,0.001412385,0.001955673,0.0006071349,0.0001309977,0.003937583,0.1123889,0.0007521837,0.01423962,0.4109442],"study_design_scores_gemma":[0.3315699,0.5036786,0.08262287,0.0002885636,0.001842748,0.004122702,0.0001838486,0.006068108,0.03611005,0.001211893,0.03206013,0.0002405998],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751608,0.01327993,0.0006537155,0.001187284,0.0004232521,0.0002986881,0.001622881,0.0003273569,0.007046204],"genre_scores_gemma":[0.9901066,0.002738265,0.0005286206,0.001131502,0.0002079174,0.0001450649,0.002535307,0.0000391942,0.002567498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003957734,"threshold_uncertainty_score":0.01323986,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04590378133135192,"score_gpt":0.3313386473117772,"score_spread":0.2854348659804253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}